All In Biotech

Drug Trial Radar · NCT07646678

A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia

A Long-term Extension Trial to Evaluate the Safety and Tolerability of TAK-360 in Participants With Selected Central Hypersomnia Conditions

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Jun 11, 2026

Primary completion

Jun 15, 2031

Study completion Jun 15, 2031

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jun 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 71 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Central hypersomnia conditions are a group of sleeping disorders where the brain has trouble keeping a person awake during the day (called excessive daytime sleepiness or EDS). These conditions usually include narcolepsy (type 1 and 2) and idiopathic hypersomnia (IH). Narcolepsy type 1 (NT1) includes sudden muscle weakness while you stay awake, called cataplexy, often triggered by strong emotions. Narcolepsy type 2 (NT2) does not include cataplexy. People with narcolepsy typically feel refreshed by short naps. People with IH feel extremely sleepy during the day, and do not feel refreshed by sleep. Waking up from sleep is difficult. This is common in the morning and also when waking up from long naps. The study wants to learn about TAK-360 when taken over a long time period; this is called a long-term extension or LTE study. The main aim of this LTE study is to find out how well participants with NT1, NT2, and IH tolerate TAK-360 over a longer period (long-term tolerability) and to learn how safe TAK-360 is when given over a longer period of time (long-term safety). Participants who completed one of the TAK-360 parent studies can join this study if they meet the study rules. Parent studies include TAK-360-2001(NCT06952699), TAK-360-2002 (NCT06812078), or other TAK-360 studies that evaluate the TAK-360 medicine. All participants will receive TAK-360 in this study. They will either receive the same dose as they did in the parent study, or the closest dose available in this LTE study. Participants who received placebo (the placebo looks just like TAK-360 but does not have any medicine in it) in their parent study will receive one of the TAK-360 doses available in this study. Placebo will only be used to not reveal the dose of TAK-360 from parent studies to investigator, participants, and sponsor. Sponsor, investigators and participants will not know which TAK-360 dose was used in the LTE study as long as the parent study is ongoing. The participants will have to visit the clinic multiple times during this study.

Conditions

  • Idiopathic Hypersomnia
  • Narcolepsy Type 1
  • Narcolepsy Type 2

Interventions

  • TAK-360Drug

    TAK-360 tablets

  • PlaceboDrug

    TAK-360-matching placebo tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE)Time frame: Up to approximately 5 years

Locations

33 sites in 5 countries. Site status is shown where the registry gives one.

  • Takeda Site 23

    Chula Vista, California · Recruiting

  • Takeda Site 25

    Santa Ana, California · Recruiting

  • Takeda Site 14

    Colorado Springs, Colorado · Recruiting

  • Takeda Site 11

    Brandon, Florida · Recruiting

  • Takeda Site 30

    Miami, Florida · Recruiting

  • Takeda Site 7

    Miami, Florida · Recruiting

  • Takeda Site 18

    Winter Park, Florida · Recruiting

  • Takeda Site 6

    Atlanta, Georgia · Recruiting

  • Takeda Site 32

    Bowie, Maryland · Recruiting

  • Takeda Site 31

    Lansing, Michigan · Recruiting

  • Takeda Site 21

    Southfield, Michigan · Recruiting

  • Takeda Site 9

    St Louis, Missouri · Recruiting

  • Takeda Site 19

    Middletown, New Jersey · Recruiting

  • Takeda Site 24

    Denver, North Carolina · Recruiting

  • Takeda Site 10

    Huntersville, North Carolina · Recruiting

  • Takeda Site 22

    Winston-Salem, North Carolina · Recruiting

  • Takeda Site 2

    Cincinnati, Ohio · Recruiting

  • Takeda Site 4

    Cincinnati, Ohio · Recruiting

  • Takeda Site 8

    Columbia, South Carolina · Recruiting

  • Takeda Site 20

    Austin, Texas · Recruiting

  • Takeda Site 3

    San Antonio, Texas · Recruiting

  • Takeda Site 33

    Norfolk, Virginia · Recruiting

  • Takeda Site 15

    Macquarie Park, New South Wales, Australia · Recruiting

  • Takeda Site 12

    Xicheng, Beijing Municipality, China · Recruiting

  • Takeda Site 5

    Guangzhou, Guangdong, China · Recruiting

  • Takeda Site 16

    Zhenzhou, Henan, China · Recruiting

  • Takeda Site 27

    Yokohama, Kanagawa, Japan · Recruiting

  • Takeda Site 13

    Kumamoto, Kumamoto, Japan · Recruiting

  • Takeda Site 29

    Isahaya-shi, Nagasaki, Japan · Recruiting

  • Takeda Site 28

    Urasoe, Okinawa, Japan · Recruiting

  • Takeda Site 26

    Osaka, Osaka, Japan · Recruiting

  • Takeda Site 1

    Shinjuku-ku, Tokyo, Japan · Recruiting

  • Takeda Site 17

    Daegu, Daegu Gwang'yeogsi, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.